查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860232

皰疹標記檢測市場：按檢測類型、技術、最終用戶和分銷管道分類 - 全球預測（2025-2032 年）

Herpes Marker Testing Market by Test Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，皰疹標記物檢測市場規模將成長 8.341 億美元，複合年成長率為 6.66%。

關鍵市場統計數據
基準年 2024 4.9786億美元
預計年份：2025年 5.3176億美元
預測年份 2032 8.341億美元
複合年成長率 (%) 6.66%

對皰疹標誌物檢測進行策略性概述，重點在於臨床效用、診斷途徑、技術趨勢以及影響決策的相關人員需求。

皰疹病毒標記檢測在現代感染疾病診斷中發揮核心作用，它將臨床決策與公共衛生監測和以患者為中心的護理聯繫起來。血清學和分子檢測技術的進步提高了診斷準確性，縮短了檢測結果的周轉時間，並將檢測能力從集中式檢查室擴展到了照護現場。臨床醫師越來越依賴抗體檢測結合核酸增幅檢查來區分原發性感染、復發性感染和無症狀感染。同時，檢查室管理者致力於整合能夠平衡靈敏度、特異性、成本和通量的工作流程。

分子診斷技術的創新、檢測的去中心化、監管政策的變化以及供應鏈的重組，推動了皰疹診斷領域技術和系統的快速變革。

皰疹診斷領域正經歷著變革性的轉變，這主要得益於技術的成熟、患者期望的不斷變化以及法規結構的調整。分子診斷技術，尤其是日益普及的即時PCR平台，提高了有症狀和無症狀病例的病毒檢測標準，提供了更高的靈敏度和更快的檢測結果。同時，血清學檢測也日趨完善。免疫檢測設計和抗原選擇的進步使得急性感染和先前感染的鑑別更加準確，而IgM和IgG結果解讀的改進也減少了診斷的不確定性。

2025年美國關稅變化對診斷採購、供應商策略和檢測途徑的營運和供應鏈影響

2025年美國關稅政策對診斷試劑供應商、檢查室採購以及皰疹病毒標記檢測的獲取途徑產生了多方面的影響。依賴跨境生產或零件採購的供應商正面臨不斷上漲的進口成本，且不同產品類型的進口成本差異很大，這給單位定價和庫存策略帶來了壓力。因此，醫院實驗室和獨立診斷網路的採購團隊正在重新審查供應商契約，延長庫存計劃週期，並重新評估標價之外的總到岸成本。

按細分市場分類的診斷趨勢：檢測類型、檢測技術、終端用戶環境和通路如何共同決定採用率和臨床效用

深入分析市場細分，可以發現檢測類型、技術平台、終端用戶環境和通路如何共同決定診斷方法的採納、使用模式和營運影響。聯合檢測與 HSV-1 或 HSV-2 特異性檢測之間的差異會影響臨床工作流程和結果解讀要求。聯合檢測提供更廣泛的診斷訊息，可以簡化初步篩檢，而特異性檢測則支援有針對性的諮詢和管理方案。

各區域（美洲、歐洲、中東和非洲、亞太地區）的測試重點和採用模式將影響准入、檢驗和分發策略。

區域趨勢對不同地區皰疹標記檢測的採用、監管和分銷產生了顯著影響。在美洲，診斷生態系統的特點是融合了綜合實驗室網路、先進的分子診斷能力，並專注於採用分散式檢查模式，以改善服務不足地區的可及性。該地區的監管機構正在逐步協調體外診斷試劑的核准流程，同時保持嚴格的檢驗標準，並鼓勵製造商投資於特定區域的臨床數據和上市後監測。

診斷開發人員、檢查室網路和技術供應商之間的競爭與合作策略決定了檢測生態系統中的成功因素和夥伴關係模式。

診斷試劑開發人員和檢測網路之間的競爭動態正在從以產品為中心的競爭演變為以合作、平台夥伴關係和服務導向差異化為特徵的更為複雜的生態系統。領先的檢測試劑製造商正在尋求整合硬體、試劑和數位化結果管理的解決方案，從而與醫院實驗室和獨立檢測網路建立更緊密的聯繫。同時，專注於快速檢測和模組化分子平台的敏捷診斷創新者則瞄準了特定的臨床需求和照護現場（POC​​）場景，在這些場景中，速度和簡便性是推動產品普及的關鍵因素。

產業領導者面臨的實際策略挑戰包括：增強供應鏈韌性、加速臨床應用以及建立永續的分銷和服務模式

產業領導者應採取一系列協同行動，以增強供應鏈韌性、加速臨床應用，並使產品系列與最終用戶需求保持一致。首先，優先考慮供應鏈透明度和多元化將降低關稅衝擊和跨境中斷的風險。各機構應整理關鍵組件的來源，評估替代供應商，並制定符合主要機構採購週期的庫存管理策略。其次，投資於模組化平台設計和可擴展的檢驗方案，將有助於在集中式實驗室和分散式臨床環境中快速部署，從而減少培訓和品管方面的阻力。

一項嚴謹的混合方法研究設計，結合了相關利益者訪談、檢查室檢驗審查、監管綜合和情境分析，確保了研究結果的可操作性。

本研究採用穩健的混合方法，對分析結果進行三角驗證，以確保其對臨床、實驗室和商業相關人員的實際意義。主要資料收集包括對實驗室主任、採購負責人、臨床專家和分銷合作夥伴進行結構化訪談，以了解決策標準、採購節奏和實際表現的考量。作為相關人員訪談的補充，檢查室檢驗審查評估了血清學和分子平台的檢測性能特徵，比較了操作要求、週轉時間和工作流程整合需求。

整合診斷趨勢、營運要務和策略路徑，指導相關人員採用和推廣皰疹標記檢測解決方案。

總體而言，研究結果凸顯了當前診斷環境中檢測效能、操作可行性和供應連續性共同決定臨床影響和應用的現狀。分子和血清學檢測技術的進步正在擴大診斷能力，而受政策變化和當地基礎設施影響的分銷和採購動態則影響實際的檢測獲取。強調採購來源多元化、投資模組化平台以及開展合作檢驗的策略性應對措施，能夠幫助機構更好地應對臨床需求和外部因素帶來的干擾。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧驅動的預測分析整合到皰疹標記檢測結果解讀中，以提高診斷準確性
  • 在基層醫療和遠端醫療環境中擴大即時皰疹病毒標記篩檢的照護現場
  • 開發一種能夠同時檢測多種皰疹病毒標記和合併感染的多重PCR平台
  • 皰疹病毒 DNA 量的定量 PCR 檢測正擴大用於指導抗病毒治療決策。
  • 透過推廣家庭檢測套組以及與數位化追蹤和遠端醫療的合作，提高病人參與。
  • 對檢驗的HSV-1和HSV-2型特異性血清學檢測的需求日益成長，這些檢測可用於孕婦篩檢和新生兒風險評估。
  • 透過實施標準化參考物質和外部品質保證計劃，在全球範圍內統一皰疹標記檢測結果。
  • 基於 CRISPR 的即時診斷檢測方法，可在資源匱乏的環境中超靈敏地檢測單純皰疹病毒標記物
  • 診斷公司與研究機構合作開發新型生物標記物，以區分活動性皰疹感染和潛伏性皰疹感染。
  • 新一代皰疹標記物檢測的監管核准正在推動市場成長，因為它可以更快地獲得檢測結果並降低檢測極限。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測方法分類的皰疹標記檢測市場

  • 聯合檢查
  • HSV-1
  • HSV-2

9. 按技術分類的皰疹標記檢測市場

  • ELISA
    • IgG ELISA
    • IgM ELISA
  • PCR
    • 常規PCR
    • 即時PCR
  • 快速檢測
    • 橫向流動化驗
    • 乳膠凝集測試
  • 西方墨點法

第10章 依最終用戶分類的皰疹標記檢測市場

  • 診所
    • 一般診所
    • 專科診所
  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢驗機構
  • 醫院
  • 研究所

第11章 皰疹標誌物檢測市場（依通路分類）

  • 直接競標
    • 政府競標
    • 機構競標
  • 醫院藥房
  • 網路藥房
    • 公司網站
    • 電子商務平台
  • 零售藥房

第12章 各地區皰疹標記檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 皰疹標記檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國皰疹標記檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • bioMerieux SA
    • Qiagen NV
    • Becton Dickinson and Company
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
Product Code: MRR-DD0700E81D12

The Herpes Marker Testing Market is projected to grow by USD 834.10 million at a CAGR of 6.66% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 497.86 million
Estimated Year [2025] USD 531.76 million
Forecast Year [2032] USD 834.10 million
CAGR (%) 6.66%

Strategic overview of herpes marker testing emphasizing clinical utility, diagnostic pathways, technological trends, and stakeholder imperatives shaping decision-making

Herpes marker testing occupies a central role in contemporary infectious disease diagnostics, connecting clinical decision-making to public health surveillance and patient-centered care. Advances in serology and molecular assays have refined diagnostic accuracy, reduced turnaround times, and expanded the settings in which testing can be delivered, from centralized laboratory environments to point-of-care contexts. Clinicians increasingly rely on a combination of antibody detection and nucleic acid amplification to differentiate between primary, recurrent, and asymptomatic infections, while laboratory directors focus on integrating workflows that balance sensitivity, specificity, cost, and throughput.

Against this technical backdrop, stakeholders across the diagnostic value chain are navigating competing pressures: rapid technological innovation, shifting reimbursement paradigms, evolving regulatory expectations, and heightened demand for accessible testing. As a result, procurement leaders and product strategists must evaluate not only assay performance characteristics but also supply chain resilience, distribution pathways, and end-user training requirements. Moreover, translational research continues to influence diagnostic guidelines, prompting laboratories to revisit algorithmic approaches to testing and reporting. In this context, the imperative for timely, actionable intelligence is clear: organizations need evidence that illuminates diagnostic performance in real-world settings, clarifies deployment trade-offs, and supports strategic investment in capabilities that deliver clinical and operational value.

Rapid technological and systemic shifts in herpes diagnostics driven by molecular innovation, decentralization of testing, regulatory change, and supply chain realignment

The landscape of herpes diagnostics is undergoing transformative shifts driven by technological maturation, changing patient expectations, and recalibrated regulatory frameworks. Molecular diagnostics, particularly increasingly accessible real-time PCR platforms, have elevated the standard for viral detection in symptomatic and asymptomatic presentations, offering both higher sensitivity and faster turnaround. At the same time, serological assays have become more nuanced; advances in immunoassay design and antigen selection enable better differentiation between acute and past exposure, and the refinement of IgM and IgG interpretation is reducing diagnostic ambiguity.

Simultaneously, decentralization of testing is reshaping care pathways. Point-of-care rapid tests that leverage lateral flow technologies now offer clinicians and community health providers pragmatic tools for immediate decision-making, while digital health integrations facilitate result reporting, patient counseling, and linkage to care. Regulatory bodies in several regions have also adjusted pathways to balance expedited access to novel diagnostics with robust post-market surveillance, prompting manufacturers to invest in data capture and real-world performance studies. Finally, supply chain diversification and strategic partnerships between assay developers, laboratory networks, and distribution platforms are accelerating the translation of innovation into routine clinical use, reinforcing a competitive environment where speed to validation and operational scalability matter as much as analytical performance.

Operational and supply chain consequences of United States tariff changes in 2025 affecting diagnostic procurement, supplier strategies, and access pathways for testing

The tariff measures implemented in the United States in 2025 have created multi-layered implications for diagnostic suppliers, laboratory procurement, and access pathways for herpes marker testing. Suppliers that rely on cross-border manufacturing and component sourcing have encountered elevated import costs that, while varying by product category, have exerted pressure on unit-level pricing and inventory strategies. Consequently, procurement teams in hospital laboratories and independent diagnostic networks have recalibrated supplier contracts, extended inventory planning horizons, and reexamined total landed costs beyond nominal list prices.

Operationally, laboratories have responded by diversifying supplier bases and accelerating evaluation of domestic or near-shore manufacturing alternatives to mitigate tariff exposure. This shift has influenced capital planning, as procurement of automated analyzers and associated consumables now factors in potential tariff-driven lead times and substitution risks. In parallel, distribution channels experienced adjustments: direct tenders and institutional procurement negotiations increasingly incorporate tariff contingencies, while online and retail pharmacy distributors reassessed pricing and margin structures to maintain service continuity.

Clinically, the cumulative effect of tariffs has manifested in constrained purchasing windows for some facilities and a heightened emphasis on assay selection criteria that balance robustness with supply reliability. Regulatory interactions have also intensified as manufacturers submit supplemental documentation to demonstrate equivalent performance for alternate sourcing arrangements. In sum, the 2025 tariff environment has underscored the strategic importance of supply chain transparency, flexible procurement models, and collaborative manufacturer-laboratory planning to sustain diagnostic access and continuity of care.

Segment-specific diagnostic dynamics showing how test types, assay technologies, end-user environments, and distribution channels jointly determine adoption and clinical utility

A nuanced view of segmentation illuminates how test type, technology platform, end-user environment, and distribution channel collectively determine diagnostic adoption, utilization patterns, and operational implications. Test type distinctions between combined assays and assays specific to HSV-1 or HSV-2 influence clinical workflows and interpretation requirements; combined assays offer diagnostic breadth that can streamline initial screening, whereas type-specific assays support targeted counseling and management pathways.

Technology segmentation further alters laboratory and clinical decisions. Enzyme-linked immunosorbent assays present as robust serological options with sub-class distinctions in IgG and IgM testing that inform timing and exposure status, while polymerase chain reaction workflows, differentiated into conventional and real-time PCR, change throughput and reporting cadence. Rapid testing modalities, encompassing lateral flow assays and latex agglutination approaches, enable near-patient diagnostic decisions and reduce time-to-action, and western blot maintains a role as a confirmatory technique in complex serological cases. These technological choices interact with end-user characteristics: general and specialized clinics, hospital laboratories and independent diagnostic labs, and research institutes each have distinct operational capacities, regulatory obligations, and patient case mixes that determine the ideal mix of assays and platforms.

Distribution channels also drive access and procurement strategies. Government and institutional tenders shape large-scale procurement cycles, hospital pharmacies coordinate inventory for inpatient and outpatient services, while online sales via company websites and e-commerce platforms, together with retail pharmacies, broaden patient access and enable alternate purchasing patterns. Taken together, this segmentation underscores the need for differentiated product strategies that account for assay performance, deployment setting, regulatory requirements, and distribution mechanics to optimize clinical impact and operational efficiency.

Regional testing priorities and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping access, validation, and distribution strategies

Regional dynamics exert a pronounced influence on the adoption, regulation, and distribution of herpes marker testing across distinct geographies. In the Americas, diagnostic ecosystems are characterized by a mix of consolidated laboratory networks, advanced molecular capacity, and an increasing emphasis on decentralized testing models to improve access in underserved areas. Regulatory agencies in this region are progressively harmonizing pathways for in vitro diagnostics while maintaining rigorous validation standards, which incentivizes manufacturers to invest in region-specific clinical data and post-market surveillance efforts.

In Europe, Middle East & Africa, variability in infrastructure and regulatory maturity creates a heterogeneous landscape in which adoption patterns differ markedly between urban, tertiary centers and peripheral facilities. This region presents significant opportunities for point-of-care technologies to expand reach, while established hospital laboratories continue to anchor confirmatory testing and advanced molecular diagnostics. Stakeholders must navigate diverse reimbursement mechanisms and import regulations, which often necessitates tailored distribution strategies and local partnerships to ensure sustained access.

Asia-Pacific demonstrates rapid uptake of both cutting-edge molecular platforms and scalable serological assays, driven by strong public health initiatives and significant private sector laboratory investment. The combination of large patient volumes, growing laboratory capacity, and proactive regulatory pathways accelerates validation timelines for novel diagnostics, yet it also requires manufacturers to address varied clinical practice patterns and local language and reporting requirements. Across all regions, alignment between technology selection, end-user capabilities, and distribution approaches will determine the success of diagnostic implementations and their impact on patient care.

Competitive and collaborative strategies among diagnostic developers, laboratory networks, and technology providers defining success factors and partnership models in testing ecosystems

Competitive dynamics among diagnostic developers and laboratory networks have evolved from product-centric rivalries to more complex ecosystems featuring collaboration, platform partnerships, and service-oriented differentiation. Leading assay manufacturers increasingly pursue integrated solutions that combine hardware, reagents, and digital result management to create stickier relationships with hospital laboratories and independent testing networks. At the same time, nimble diagnostic innovators focusing on rapid assays or modular molecular platforms target niche clinical needs and point-of-care scenarios where speed and simplicity drive adoption.

Laboratory groups, including hospital laboratories and independent diagnostic providers, are differentiating through consolidated testing menus, quality assurance programs, and value-added reporting that contextualizes serological and molecular results for clinicians. Strategic alliances between manufacturers and distribution partners enhance reach into government tender channels and institutional procurement cycles, while direct-to-provider and online distribution strategies expand patient-facing access. Additionally, partnerships with research institutes facilitate clinical validation studies and support regulatory submissions, enabling faster real-world evidence generation. In this environment, competitive advantage accrues to organizations that combine rigorous analytical performance with supply chain reliability, flexible commercial models, and services that simplify implementation for end users across clinical and community settings.

Practical strategic imperatives for industry leaders to strengthen supply resilience, accelerate clinical adoption, and build sustainable distribution and service models

Industry leaders should pursue a set of coordinated actions that enhance supply resilience, accelerate clinical adoption, and align product portfolios with end-user requirements. First, prioritizing supply chain transparency and diversification will reduce exposure to tariff shocks and cross-border disruptions; organizations should map critical component sourcing, qualify alternate suppliers, and build inventory management strategies that reflect procurement cycles of major institutional buyers. Second, investing in modular platform designs and scalable validation packages will enable faster deployment across both centralized laboratories and decentralized care settings, while reducing the friction associated with training and quality control.

Third, cultivating collaborative relationships with hospital systems, independent laboratories, and research institutes will expedite real-world performance studies and streamline regulatory interactions; these partnerships can also support joint educational initiatives that improve clinician interpretation of serological and molecular results. Fourth, aligning distribution strategies to account for government tenders, institutional purchasing, hospital pharmacy logistics, and e-commerce channels will broaden access while permitting differentiated pricing and service models. Finally, embedding digital result reporting, patient linkage to care pathways, and analytics to monitor post-market performance will create a value proposition that extends beyond the assay itself, supporting sustained uptake and evidence-based refinements to product offerings.

Rigorous mixed-methods research design combining stakeholder interviews, laboratory validation reviews, regulatory synthesis, and scenario mapping to ensure actionable findings

The research employed a robust mixed-methods approach designed to triangulate analytical findings and ensure practical relevance for clinical, laboratory, and commercial stakeholders. Primary data collection included structured interviews with laboratory directors, procurement officials, clinical specialists, and distribution partners to capture decision-making criteria, procurement rhythms, and real-world performance considerations. Complementing stakeholder interviews, laboratory validation reviews evaluated assay performance characteristics across serological and molecular platforms, comparing operational requirements, turnaround times, and workflow integration needs.

Secondary analysis synthesized regulatory documentation, peer-reviewed literature, and clinical guideline updates to contextualize technological changes and interpret implications for deployment. The methodology incorporated scenario mapping to assess supply chain and procurement responses under different policy and operational conditions, and data synthesis prioritized reproducibility and transparency through documented inclusion criteria and analytical procedures. Throughout, findings were cross-checked with subject-matter experts to validate interpretations and ensure recommendations reflect implementable actions in diverse clinical and institutional environments.

Synthesis of diagnostic trends, operational imperatives, and strategic pathways to guide stakeholders as they implement and scale herpes marker testing solutions

In aggregate, the evidence highlights a diagnostic landscape in which assay performance, operational feasibility, and supply continuity jointly determine clinical impact and adoption. Technological advances in molecular and serological testing are expanding diagnostic capabilities, while distribution and procurement dynamics, shaped by policy changes and regional infrastructure, influence actual access to testing. Strategic responses that emphasize diversified sourcing, modular platform investments, and collaborative validation efforts will position organizations to respond to both clinical demand and external disruptions.

Moving forward, stakeholders that integrate rigorous validation, clinician education, and flexible commercial models will realize the greatest clinical and operational returns. The interplay between rapid point-of-care solutions and centralized laboratory confirmatory testing will continue to define diagnostic pathways, and organizations that proactively align product development with end-user workflows and regional regulations will be better prepared to deliver consistent, patient-centered diagnostic services. Ultimately, the path to sustained success lies in balancing innovation with pragmatic implementation strategies that prioritize reliability, interpretability, and equitable access across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven predictive analytics in herpes marker test interpretation to improve diagnostic accuracy
  • 5.2. Expansion of point-of-care herpes simplex virus marker assays to primary care and telemedicine settings for rapid screening
  • 5.3. Development of multiplex PCR platforms enabling simultaneous detection of multiple herpesvirus markers and co-infections
  • 5.4. Growing adoption of quantitative PCR testing for herpesviral DNA loads to guide antiviral therapy decisions
  • 5.5. Rise of at-home herpes marker testing kits with digital follow-up telehealth integration enhancing patient engagement
  • 5.6. Increase in demand for HSV-1 and HSV-2 type-specific serological assays validated for maternal screening and neonatal risk assessment
  • 5.7. Implementation of standardized reference materials and external quality assurance programs to harmonize herpes marker testing results globally
  • 5.8. Emergence of CRISPR-based point-of-care diagnostic assays offering ultra-sensitive detection of herpes simplex virus markers in low-resource settings
  • 5.9. Partnerships between diagnostic companies and research institutions to develop novel biomarkers differentiating between active and latent herpes infections
  • 5.10. Regulatory approvals of next-generation herpes marker tests with shorter turnaround times and lower limits of detection driving market growth

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Herpes Marker Testing Market, by Test Type

  • 8.1. Combined
  • 8.2. Hsv-1
  • 8.3. Hsv-2

9. Herpes Marker Testing Market, by Technology

  • 9.1. Elisa
    • 9.1.1. Igg Elisa
    • 9.1.2. Igm Elisa
  • 9.2. Pcr
    • 9.2.1. Conventional Pcr
    • 9.2.2. Real-Time Pcr
  • 9.3. Rapid Test
    • 9.3.1. Lateral Flow Assay
    • 9.3.2. Latex Agglutination
  • 9.4. Western Blot

10. Herpes Marker Testing Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Clinics
    • 10.1.2. Specialized Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Hospital Labs
    • 10.2.2. Independent Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Herpes Marker Testing Market, by Distribution Channel

  • 11.1. Direct Tender
    • 11.1.1. Government Tender
    • 11.1.2. Institutional Tender
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
    • 11.3.1. Company Websites
    • 11.3.2. E-Commerce Platforms
  • 11.4. Retail Pharmacies

12. Herpes Marker Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Herpes Marker Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Herpes Marker Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Danaher Corporation
    • 15.3.6. bioMerieux SA
    • 15.3.7. Qiagen NV
    • 15.3.8. Becton Dickinson and Company
    • 15.3.9. DiaSorin S.p.A.
    • 15.3.10. Bio-Rad Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HERPES MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HERPES MARKER TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HERPES MARKER TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)